Inflammation
Conditions
Keywords
Mobility
Brief summary
ENRGISE Pilot Study will test the ability of anti-inflammatory interventions for preventing major mobility disability by improving or preserving walking ability.
Detailed description
Growing evidence shows that low-grade chronic inflammation, characterized by elevations in plasma C-reactive protein, tumor necrosis factor alpha, and particularly Interleukin-6 (IL-6), is an independent risk factor of disability, impaired mobility, and lower walking speed. Low-grade chronic inflammation is a modifiable risk factor. However, it is unknown whether interventions that reduce the levels of inflammatory markers per se improve mobility, or avert decline in mobility in older persons. To address this gap in evidence the investigators are conducting the randomized clinical trial ENRGISE (ENabling Reduction of low-Grade Inflammation in SEniors) Pilot Study to test the ability of anti-inflammatory interventions for preventing major mobility disability by improving or preserving walking ability. We have maximized the public health impact by selecting interventions that are safe, tolerable, acceptable, and affordable for vulnerable older persons. Specifically, in this trial the investigators test the efficacy verus placebo of the angiotensin receptor blocker losartan and omega-3 polyunsaturated fatty acids in the form of fish oil, alone and in combination. Both angiotensin receptor blockers and omega-3 polyunsaturated fatty acids have shown to reduce IL-6 in clinical trials and preliminary data suggest that they may improve physical function. Recruitment will include the older persons who are at risk for, or with, mobility impairment, as measured by slow gait speed and self-reported mobility difficulty, and who have elevated levels of IL-6, the marker most consistently associated with mobility limitations. Preliminary data regarding feasibility need to be gathered before such a trial can be effectively designed and implemented. We conduct The ENRGISE Pilot Study to assess the effects of the interventions on several inflammatory markers, walking speed, physical function and strength. This allows us to refine the design, recruitment yields, target population, adherence, retention, tolerability, sample-size, and cost for the main ENRGISE trial.
Interventions
DIETARY_SUPPLEMENTOmega-3 fish oil
The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
DRUGLosartan
The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
OTHERCorn Oil (Fish oil Placebo)
The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
OTHERCellulose Based (Losartan Placebo)
The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
Sponsors
National Institute on Aging (NIA)
Abbott
University of Florida
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women age \>70 years * Self-reported difficulty walking ¼ of a mile or climbing a flight of stairs * Walking speed \<1 meters per second and \>0.44 meters per second on the 4 meter walk at usual pace. A walking speed of \<0.44 meters per second would not be compatible with completing the 400 meter walk in 15 minutes. (In the pilot phase we explore the feasibility of recruiting at least 50% of participants who have a baseline walking speed of \<0.80 meters per second and \>0.44 meters per second) * Able to complete the 400 meter walk test within 15 minutes without sitting or the help of another person and without a walker, a cane is allowed * Blood level IL-6 \>2.5 pg/ml and \<30 pg/ml. * Willingness to be randomized to the intervention groups
Exclusion criteria
* Failure or inability to provide informed consent * Lives in a nursing home; persons living in assisted or independent housing are not excluded * Self-reported inability to walk one block * Significant cognitive impairment, defined as a known diagnosis of dementia, or a Mini-Mental State Exam (MMSE) score \<24 (\<23 for racial/ethnic minorities or participants with less than 9 years of education) * Unable to communicate because of severe hearing loss or speech disorder * Neurological conditions that are causing impaired muscle function or mobility (may include stroke with residual paresis, paralysis, neuropathy, Parkinson disease, or multiple sclerosis) * Severe rheumatologic or orthopedic diseases, e.g., awaiting joint replacement, known active inflammatory or autoimmune disease (e.g. rheumatoid arthritis, lupus, Crohn's disease, HIV) * Terminal illness with life expectancy less than 12 months * Severe pulmonary disease, requiring either steroid pills or injections * Other significant co-morbid disease that in the opinion of the field center PI would impair ability to participate in the trial, e.g. renal failure on hemodialysis, severe psychiatric disorder (e.g. bipolar, schizophrenia), excessive alcohol use (\>14 drinks per week); drug addiction; treatment for cancer (radiation or chemotherapy) within the past 1 year; or other conditions * Lives outside of the study site or is planning to move out of the area in next 1 year or leave the area for \>3 months during the next year *
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the Interleukin-6 Level Between Groups | Changes from baseline to month 12 | Changes in the Interleukin-6 Level Between the Groups |
| Number of Participants Experiencing Major Mobility Disability | 12 months | The 400 meter walk test at usual pace is used to evaluate major mobility disability (MMD), defined as the inability to walk ¼ mile or 400 meters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Isometric Hand Grip Strength | 12 months | The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles. Scoring will be taken from the best results of 3 trials. Males scores range from 88 pounds as very poor to 141 pounds as excellent with an average of 105-113 pounds. Females scores range from 44 pounds as very poor to 84 pounds as excellent with an average of 57-65 pounds. |
| Short Physical Performance Battery (SPPB) | 12 months | A low score on the SPPB based on 4 m walk, balance & chair stands tests is a risk factor for disability, institutionalization, morbidity and mortality in initially non-disabled older persons. The summary score and components of the SPPB have good reliability (ICCs range from 0.88 to 0.92). Higher scores are better. Range 0-12. |
| Short Form Health Survey (SF-36) - Physical Component Score | month 12 | The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Range: 0-100. A lower score indicates more disability, i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. |
| Peak Torque of the Knee Extensor and Flexor Muscles | month 12 | Peak torque was measured at a rotational speed of 60 degrees per second using a commercially-available Isokinetic Dynamometer (Biodex). Torque was measured during maximal knee extension and flexion reported in Newton Meters. |
| Number of Participants Exhibiting Frailty | 12 months | Frailty will be characterized with Fried criteria developed by Fried et al. that employ self-reported exhaustion, unintentional weight loss, low energy expenditure, slow gait speed, and weak grip strength. Those with \>3 of the 5 factors are judged to be frail, those with 1 or 2 factors as pre-frail, and those with no factors as non-frail. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Fish Oil Active This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
Omega-3 fish oil: The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day. | 109 |
| Fish Oil Placebo This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
Corn Oil (Fish oil Placebo): The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil. | 71 |
| Losartan Active This group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
Losartan: The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day. | 26 |
| Losartan Placebo This group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan.
Cellulose Based (Losartan Placebo): The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules. | 17 |
| Fish Oil Active + Losartan Active This group will receive both the Losartan and Omega-3 fish oil. Losartan will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
Omega-3 fish oil will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams/day for the remaining six month.
Omega-3 fish oil: The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screenin | 26 |
| Fish Oil Active + Losartan Placebo This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams/day for the remaining six month.
In addition, this group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan.
Omega-3 fish oil: The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by \>40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
Cellulose Based (Losartan Placeb | 13 |
| Fish Oil Placebo + Losartan Active This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
In addition, this group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams /day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
Losartan: The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measure | 13 |
| Fish Oil Placebo + Losartan Placebo This group will receive a placebo which will be matching to both the omega-3 fish oil and losartan which will be administered at doses corresponding to doses administered for omega-3 fish oil and losartan throughout the 12 month study.
Corn Oil (Fish oil Placebo): The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
Cellulose Based (Losartan Placebo): The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules. | 14 |
| Total | 289 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Death | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 4 | 3 | 1 | 0 | 3 | 1 | 1 | 1 |
Baseline characteristics
| Characteristic | Fish Oil Active | Fish Oil Placebo | Losartan Active | Losartan Placebo | Fish Oil Active + Losartan Active | Fish Oil Active + Losartan Placebo | Fish Oil Placebo + Losartan Active | Fish Oil Placebo + Losartan Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 109 Participants | 71 Participants | 26 Participants | 17 Participants | 26 Participants | 13 Participants | 13 Participants | 14 Participants | 289 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous | 78 years STANDARD_DEVIATION 5 | 77 years STANDARD_DEVIATION 5 | 78 years STANDARD_DEVIATION 5 | 77 years STANDARD_DEVIATION 6 | 77 years STANDARD_DEVIATION 6 | 79 years STANDARD_DEVIATION 7 | 76 years STANDARD_DEVIATION 5 | 78 years STANDARD_DEVIATION 5 | 78 years STANDARD_DEVIATION 5 |
| IL-6 | 3.7 pg/ml STANDARD_DEVIATION 1.5 | 4.4 pg/ml STANDARD_DEVIATION 1.7 | 3.5 pg/ml STANDARD_DEVIATION 1.3 | 5.7 pg/ml STANDARD_DEVIATION 3.7 | 2.8 pg/ml STANDARD_DEVIATION 1.6 | 3.1 pg/ml STANDARD_DEVIATION 1.4 | 4.3 pg/ml STANDARD_DEVIATION 1.2 | 4.2 pg/ml STANDARD_DEVIATION 1.6 | 3.9 pg/ml STANDARD_DEVIATION 1.7 |
| Race/Ethnicity, Customized Minority (non-white only),self-report | 24 Participants | 14 Participants | 9 Participants | 3 Participants | 4 Participants | 3 Participants | 3 Participants | 4 Participants | 64 Participants |
| Region of Enrollment United States | 109 participants | 71 participants | 26 participants | 17 participants | 26 participants | 13 participants | 13 participants | 14 participants | 289 participants |
| Sex: Female, Male Female | 58 Participants | 37 Participants | 15 Participants | 12 Participants | 14 Participants | 6 Participants | 6 Participants | 4 Participants | 152 Participants |
| Sex: Female, Male Male | 51 Participants | 34 Participants | 11 Participants | 5 Participants | 12 Participants | 7 Participants | 7 Participants | 10 Participants | 137 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 109 | 2 / 71 | 1 / 26 | 0 / 17 | 0 / 26 | 0 / 13 | 0 / 13 | 0 / 14 |
| other Total, other adverse events | 73 / 109 | 46 / 71 | 22 / 26 | 16 / 17 | 20 / 26 | 12 / 13 | 10 / 13 | 11 / 14 |
| serious Total, serious adverse events | 30 / 109 | 17 / 71 | 3 / 26 | 4 / 17 | 8 / 26 | 3 / 13 | 2 / 13 | 5 / 14 |
Outcome results
Primary
Changes in the Interleukin-6 Level Between Groups
Changes in the Interleukin-6 Level Between the Groups
Time frame: Changes from baseline to month 12
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Fish Oil Active | Changes in the Interleukin-6 Level Between Groups | 0 pg/ml | Standard Deviation 2.4 |
| Fish Oil Placebo | Changes in the Interleukin-6 Level Between Groups | -0.1 pg/ml | Standard Deviation 2.7 |
| Losartan Active | Changes in the Interleukin-6 Level Between Groups | -0.6 pg/ml | Standard Deviation 1 |
| Losartan Placebo | Changes in the Interleukin-6 Level Between Groups | 3.8 pg/ml | Standard Deviation 10 |
| Fish Oil Active + Losartan Active | Changes in the Interleukin-6 Level Between Groups | -0.3 pg/ml | Standard Deviation 1 |
| Fish Oil Active + Losartan Placebo | Changes in the Interleukin-6 Level Between Groups | -0.2 pg/ml | Standard Deviation 1.8 |
| Fish Oil Placebo + Losartan Active | Changes in the Interleukin-6 Level Between Groups | -1.4 pg/ml | Standard Deviation 0.9 |
| Fish Oil Placebo + Losartan Placebo | Changes in the Interleukin-6 Level Between Groups | -1.0 pg/ml | Standard Deviation 2.8 |
Primary
Number of Participants Experiencing Major Mobility Disability
The 400 meter walk test at usual pace is used to evaluate major mobility disability (MMD), defined as the inability to walk ¼ mile or 400 meters.
Time frame: 12 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Fish Oil Active | Number of Participants Experiencing Major Mobility Disability | 20 Participants |
| Fish Oil Placebo | Number of Participants Experiencing Major Mobility Disability | 5 Participants |
| Losartan Active | Number of Participants Experiencing Major Mobility Disability | 4 Participants |
| Losartan Placebo | Number of Participants Experiencing Major Mobility Disability | 15 Participants |
| Fish Oil Active + Losartan Active | Number of Participants Experiencing Major Mobility Disability | 4 Participants |
| Fish Oil Active + Losartan Placebo | Number of Participants Experiencing Major Mobility Disability | 3 Participants |
| Fish Oil Placebo + Losartan Active | Number of Participants Experiencing Major Mobility Disability | 7 Participants |
| Fish Oil Placebo + Losartan Placebo | Number of Participants Experiencing Major Mobility Disability | 3 Participants |
Secondary
Isometric Hand Grip Strength
The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles. Scoring will be taken from the best results of 3 trials. Males scores range from 88 pounds as very poor to 141 pounds as excellent with an average of 105-113 pounds. Females scores range from 44 pounds as very poor to 84 pounds as excellent with an average of 57-65 pounds.
Time frame: 12 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Fish Oil Active | Isometric Hand Grip Strength | 24.8 pounds | Standard Deviation 8.5 |
| Fish Oil Placebo | Isometric Hand Grip Strength | 25.3 pounds | Standard Deviation 7.3 |
| Losartan Active | Isometric Hand Grip Strength | 25.9 pounds | Standard Deviation 9.2 |
| Losartan Placebo | Isometric Hand Grip Strength | 27.5 pounds | Standard Deviation 11 |
| Fish Oil Active + Losartan Active | Isometric Hand Grip Strength | 22.4 pounds | Standard Deviation 9.5 |
| Fish Oil Active + Losartan Placebo | Isometric Hand Grip Strength | 19.8 pounds | Standard Deviation 8.7 |
| Fish Oil Placebo + Losartan Active | Isometric Hand Grip Strength | 27.6 pounds | Standard Deviation 8.4 |
| Fish Oil Placebo + Losartan Placebo | Isometric Hand Grip Strength | 23.6 pounds | Standard Deviation 10.1 |
Secondary
Number of Participants Exhibiting Frailty
Frailty will be characterized with Fried criteria developed by Fried et al. that employ self-reported exhaustion, unintentional weight loss, low energy expenditure, slow gait speed, and weak grip strength. Those with \>3 of the 5 factors are judged to be frail, those with 1 or 2 factors as pre-frail, and those with no factors as non-frail.
Time frame: 12 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Fish Oil Active | Number of Participants Exhibiting Frailty | 15 Participants |
| Fish Oil Placebo | Number of Participants Exhibiting Frailty | 3 Participants |
| Losartan Active | Number of Participants Exhibiting Frailty | 4 Participants |
| Losartan Placebo | Number of Participants Exhibiting Frailty | 1 Participants |
| Fish Oil Active + Losartan Active | Number of Participants Exhibiting Frailty | 3 Participants |
| Fish Oil Active + Losartan Placebo | Number of Participants Exhibiting Frailty | 3 Participants |
| Fish Oil Placebo + Losartan Active | Number of Participants Exhibiting Frailty | 1 Participants |
| Fish Oil Placebo + Losartan Placebo | Number of Participants Exhibiting Frailty | 1 Participants |
Secondary
Peak Torque of the Knee Extensor and Flexor Muscles
Peak torque was measured at a rotational speed of 60 degrees per second using a commercially-available Isokinetic Dynamometer (Biodex). Torque was measured during maximal knee extension and flexion reported in Newton Meters.
Time frame: month 12
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Fish Oil Active | Peak Torque of the Knee Extensor and Flexor Muscles | 81.3 Newton meters | Standard Deviation 34 |
| Fish Oil Placebo | Peak Torque of the Knee Extensor and Flexor Muscles | 77.7 Newton meters | Standard Deviation 30.8 |
| Losartan Active | Peak Torque of the Knee Extensor and Flexor Muscles | 87.6 Newton meters | Standard Deviation 35.5 |
| Losartan Placebo | Peak Torque of the Knee Extensor and Flexor Muscles | 78.6 Newton meters | Standard Deviation 28.6 |
| Fish Oil Active + Losartan Active | Peak Torque of the Knee Extensor and Flexor Muscles | 85.3 Newton meters | Standard Deviation 29.8 |
| Fish Oil Active + Losartan Placebo | Peak Torque of the Knee Extensor and Flexor Muscles | 76.6 Newton meters | Standard Deviation 19.2 |
| Fish Oil Placebo + Losartan Active | Peak Torque of the Knee Extensor and Flexor Muscles | 84.0 Newton meters | Standard Deviation 52.8 |
| Fish Oil Placebo + Losartan Placebo | Peak Torque of the Knee Extensor and Flexor Muscles | 86.1 Newton meters | Standard Deviation 24.5 |
Secondary
Short Form Health Survey (SF-36) - Physical Component Score
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Range: 0-100. A lower score indicates more disability, i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: month 12
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Fish Oil Active | Short Form Health Survey (SF-36) - Physical Component Score | 41.9 score on a scale | Standard Deviation 7.9 |
| Fish Oil Placebo | Short Form Health Survey (SF-36) - Physical Component Score | 42.6 score on a scale | Standard Deviation 9.7 |
| Losartan Active | Short Form Health Survey (SF-36) - Physical Component Score | 41.8 score on a scale | Standard Deviation 9.8 |
| Losartan Placebo | Short Form Health Survey (SF-36) - Physical Component Score | 41.3 score on a scale | Standard Deviation 9 |
| Fish Oil Active + Losartan Active | Short Form Health Survey (SF-36) - Physical Component Score | 41.9 score on a scale | Standard Deviation 8.6 |
| Fish Oil Active + Losartan Placebo | Short Form Health Survey (SF-36) - Physical Component Score | 42.7 score on a scale | Standard Deviation 8.2 |
| Fish Oil Placebo + Losartan Active | Short Form Health Survey (SF-36) - Physical Component Score | 46.6 score on a scale | Standard Deviation 7.4 |
| Fish Oil Placebo + Losartan Placebo | Short Form Health Survey (SF-36) - Physical Component Score | 47.9 score on a scale | Standard Deviation 6.7 |
Secondary
Short Physical Performance Battery (SPPB)
A low score on the SPPB based on 4 m walk, balance & chair stands tests is a risk factor for disability, institutionalization, morbidity and mortality in initially non-disabled older persons. The summary score and components of the SPPB have good reliability (ICCs range from 0.88 to 0.92). Higher scores are better. Range 0-12.
Time frame: 12 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Fish Oil Active | Short Physical Performance Battery (SPPB) | 8.6 units on a scale | Standard Deviation 2.3 |
| Fish Oil Placebo | Short Physical Performance Battery (SPPB) | 8.1 units on a scale | Standard Deviation 2.5 |
| Losartan Active | Short Physical Performance Battery (SPPB) | 8.2 units on a scale | Standard Deviation 2.5 |
| Losartan Placebo | Short Physical Performance Battery (SPPB) | 8.4 units on a scale | Standard Deviation 2.7 |
| Fish Oil Active + Losartan Active | Short Physical Performance Battery (SPPB) | 8.6 units on a scale | Standard Deviation 2.5 |
| Fish Oil Active + Losartan Placebo | Short Physical Performance Battery (SPPB) | 7.3 units on a scale | Standard Deviation 2.1 |
| Fish Oil Placebo + Losartan Active | Short Physical Performance Battery (SPPB) | 8.5 units on a scale | Standard Deviation 2.1 |
| Fish Oil Placebo + Losartan Placebo | Short Physical Performance Battery (SPPB) | 9.1 units on a scale | Standard Deviation 2 |